Literature DB >> 5778785

Gene control of hematopoiesis. I. Erythrocyte mosaicism and permanent immunological tolerance in allophenic mice.

B Mintz, J Palm.   

Abstract

Erythropoietic cells of two unrelated strains, C3H (or C3Hf) and C57BL/6, can coexist throughout hematopoiesis in allophenic mice experimentally produced from aggregated, undifferentiated blastomeres of separate genotypes. The presence of two red cell genotypes in these circumstances signifies that the erythroid population must normally be multiclonal, i.e., derived mitotically from at least two genetically determined cells. The two strains were detected by hemagglutination and absorption tests of erythrocytes for the specific histocompatibility antigens dictated by the H-2(k) and H-2(b) alleles. Of 34 C3H(f) <--> C57BL/6 allophenics tested, 16 had both red cell types; the remaining 18 showed only C3H or C57 red cells and included 12 mice with both cell strains present in some other tissues. All animals with evidence of two H-2 phenotypes among circulating erythrocytes were permanently immunologically tolerant of both antigenic types and remained free of runt disease. They lived a full lifespan, up to 2 yr 7(1/2) months of age. The data suggest a possible specific selective advantage of C57BL/6 over C3H erythropoietic tissue. There is considerable individual variability, not only in proportions of antigenically distinct erythrocytes, but also in strain composition of other tissues in the same animals. A broad spectrum of distinctive situations is found, in which parameters are varied within or outside of the circulatory system. Allophenic mice can therefore serve as investigative tools for entirely new kinds of experimental studies of gene control mechanisms and blood physiology in normal hematopoiesis and in a number of hereditary blood diseases.

Entities:  

Mesh:

Year:  1969        PMID: 5778785      PMCID: PMC2138637          DOI: 10.1084/jem.129.5.1013

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  POSSIBLE SOMATIC CELL MATING IN TWIN CATTLE WITH ERYTHROCYTE MOSAICISM.

Authors:  W H STONE; J FRIEDMAN; A FREGIN
Journal:  Proc Natl Acad Sci U S A       Date:  1964-06       Impact factor: 11.205

2.  SELECTION IN MAMMALIAN MOSAIC CELL POPULATIONS.

Authors:  S M GARTLER; D LINDER
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1964

3.  Histocompatibility genes of the mouse. II. Production and analysis of isogenic resistant lines.

Authors:  G D SNELL; R B JACKSON
Journal:  J Natl Cancer Inst       Date:  1958-11       Impact factor: 13.506

4.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

5.  Identification of a gene locus for gamma-G-1 immunoglobulin H chains and its linkage to the H chain chromosome region in the mouse.

Authors:  J D Minna; G M Iverson; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1967-07       Impact factor: 11.205

6.  Subunit structure and gene control of mouse NADP-malate dehydrogenase.

Authors:  W W Baker; B Mintz
Journal:  Biochem Genet       Date:  1969-01       Impact factor: 1.890

7.  Gene control of mammalian pigmentary differentiation. I. Clonal origin of melanocytes.

Authors:  B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1967-07       Impact factor: 11.205

8.  "Intrinsic" immunological tolerance in allophenic mice.

Authors:  B Mintz; W K Silvers
Journal:  Science       Date:  1967-12-15       Impact factor: 47.728

9.  SKIN GRAFTS: DELAYED REJECTION BETWEEN PAIRS OF CATTLE TWINS SHOWING ERYTHROCYTE CHIMERISM.

Authors:  W H STONE; R G CRAGLE; E W SWANSON; D G BROWN
Journal:  Science       Date:  1965-06-04       Impact factor: 47.728

10.  THE IMMUNOGLOBULINS OF MICE. II. TWO SUBCLASSES OF MOUSE 7S GAMMA-2-GLOBULINS: GAMMA-2A- AND GAMMA-2B-GLOBULINS.

Authors:  J L FAHEY; J WUNDERLICH; R MISHELL
Journal:  J Exp Med       Date:  1964-08-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Individuality in disease and therapy.

Authors:  B Cinader
Journal:  Can Med Assoc J       Date:  1975-07-12       Impact factor: 8.262

2.  An extreme bias in the germ line of XY C57BL/6<->XY FVB/N chimaeric mice.

Authors:  G R MacGregor
Journal:  Reproduction       Date:  2002-09       Impact factor: 3.906

3.  Immunofluorescence and elution studies in tetraparental NZB forms and is formed from CFW chimaeras and graft-versus-host diseased NZB.

Authors:  R D Barnes; J Holliday; M Tuffrey
Journal:  Immunology       Date:  1974-06       Impact factor: 7.397

4.  The disease of the NZB mouse. I. Examination of ovum fusion derived tetraparental NZB:CFW chimaeras.

Authors:  R D Barnes; M Tuffrey; J Kingman; C Thornton; M W Turner
Journal:  Clin Exp Immunol       Date:  1972-08       Impact factor: 4.330

5.  Tetraparental sheep chimaeras induced by blastomere transplantation. Changes in blood type with age.

Authors:  E M Tucker; R M Moor; L E Rowson
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

6.  The delay of leukaemia in tetraparental ovum fusion-derived AKR chimaeras.

Authors:  R D Barnes; M Tuffrey; J Kingman
Journal:  Clin Exp Immunol       Date:  1972-12       Impact factor: 4.330

7.  Production of viable adult trisomy 17 reversible diploid mouse chimeras.

Authors:  C J Epstein; S A Smith; T Zamora; J A Sawicki; T R Magnuson; D R Cox
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

Review 8.  Do cells fuse in vivo?

Authors:  B Mintz
Journal:  In Vitro       Date:  1970

9.  Antibody response of C3H in equilibrium (CKB X CWB)F1 tetraparental mice to poly-L(Tyr,Glu)-poly-D,L-Ala-poly-L-Lys immunization.

Authors:  K B Bechtol; H O McDevitt
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

10.  Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity.

Authors:  Alexander Y Wagner; Eric Holle; Lori Holle; Xianzhong Yu; Günter Schwamberger
Journal:  BMC Cancer       Date:  2008-12-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.